Avidex Limited, a Milton Park, U.K.-based biotechnology company, and Dow Chemical have agreed to collaborate in the creation of biotargeted radiopharmaceuticals for cancer treatment. Under the agreement, proprietary chelation technology and other capabilities, provided through ChelaMed radiopharmaceutical services from Dow, will be used to attach a therapeutic radioisotope to a targeted monoclonal T-cell receptor (mTCR).
The first joint effort will focus on Avidex’s mTCR product, EsoDex, to further enhance the targeted radiopharmaceutical for treatment of lung and bladder cancer, the companies said. The firms plan on using the Dow chelator to attach a radionuclide (such as yttrium-90 or lutetium-177) as a payload to the NY-ESO antigen-specific mTCR to enable targeted delivery of cytotoxic agents.
By AuntMinnie.com staff writersSeptember 2, 2003
Related Reading
Cytogen reacquires Quadramet rights, August 1, 2003
Copyright © 2003 AuntMinnie.com
